Proteomic & lipidomic studies, preclinical pharmacokinetics & toxicokinetics, metabolic profiling of chemical entities in discovery and formulation development phase; analytical and bioanalytical method development & validation using HPLC, UPLC, LC-MS/MS; impurity profiling, characterization, compatibility and stability analysis of pharmaceuticals.

• September 2017 – Present:
  Assistant Professor, Department of Pharmaceutical Analysis, NIPER Ahmedabad, Gujarat, India.
• July 2016 – August 2017
  Assistant Professor, Department of Pharmaceutical Technology, International Islamic University Malaysia, Pahang, Malaysia.
• July 2014 - June 2016:
  Senior Lecturer and Head of the Department, Pharmaceutical Chemistry, Faculty of Pharmacy, Lincoln University College, Selangor, Malaysia.
• March 2011 – June 2014:
  Senior Executive, Analytical Development, Quality Control department, Fresenius Kabi Oncology Ltd, India.
• November 2007 – February 2011:
  SRF-AICTE, Bioequivalence Study Centre, Jadavpur University, India.
• July 2006 – October 2007:
  Junior Scientist, Drug Metabolism and Pharmacokinetics department, Discovery Research division, Dr. Reddys Lab Ltd., India.

• ‘Professor Anupam Sengupta Memorial Medal’ for academic excellence in Pharmaceutical Chemistry in M. Pharm awarded by Jadavpur University, India (2006).
• ‘Best Oral Presentation Award of ICCE, Thailand’ in International Congress of Chemistry and Environment Conference (ICCE) at Ubonrathchathani, Thailand (2010).
• National Doctoral Fellowship (NDF) awarded by All India Council for Technical Education (AICTE), India (2009).
• UGC Research Fellowship in Science for Meritorious Students awarded by University Grant Commission (UGC), India (2008).
• UGC Scholarship for pursuing M. Pharm., awarded by University Grant Commission (UGC), India (2004).

Grants

• Title: Naso-mucosal absorption of neuronal drug by sol-to-gel delivery system to target brain: approach to dose reduction.
• Tenure: 2 years 2 months.
• Funded by: Ministry of Higher Education, Govt. of Malaysia, Fundamental Research Grant Scheme (FRGS).
• Title: Evaluation of safety profile of a Fixed dose combination of Antidiabetic and Antihypertensive drug by toxicity profiling and pharmacokinetic interaction study.
• Tenure: 2 years
• Funded by: Ministry of Higher Education, Govt. of Malaysia, Fundamental Research Grant Scheme (FRGS).
• Title: Optimization of asiaticoside purification from Centella asiatica extract and development of asiaticoside gel formulation for topical application.
• Tenure:1 year
• Funded by: IIUM, Govt. of Malaysia, Research Initiative Grant Scheme (RIGS).
• Title: Aqueous gel based topical nanoemulsion; An approach to enhance the bioavailability of lipophilic drugs.
• Tenure:1 year
• Funded by: IIUM, Govt. of Malaysia, Research Initiative Grant Scheme (RIGS).

Consultancies

• Consultant for IIUM Bioequivalence Study Centre (iBEST), 25200 Kuantan, Pahang, Malaysia.

• Development and validation of a high throughput LC-MS/MS method for simultaneous quantitation of pioglitazone and telmisartan in rat plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical Analysis, 2017. 7; 381–387. Impact Factor: 14.026.
• Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2022. 215, 114753. Impact Factor: 3.571.
• Critical strategies to pinpoint carryover problems in liquid chromatography-mass spectrometry: a systematic direction for their origin identification and mitigation. Microchemical Journal. 2022. 179, 107464. Impact Factor: 5.304.
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: A needful consideration towards modern anticancer drug discovery. Drug Metabolism Reviews. 2022, https://doi.org/10.1080/03602532.2022.2048007. Impact Factor: 6.984.
• Engineering immunity via skin-directed drug delivery devices. Journal of Controlled Release. 2022, 345, 385-404. Impact Factor: 11.467.
• A systematic UHPLC-Q-TOF-MS/MS based analytical approach for characterization of flibanserin metabolites and establishment of biotransformation pathway. Journal of Chromatography B, 2021, 1185, 123011. Impact Factor: 3.318.
• Biosimilars accessible in the market for the treatment of cancer. Journal of Controlled Release. 2021, 336, 112-129. Impact Factor: 11.467.
• A mechanistic explanation on degradation behavior of flibanserin for identification and characterization of its potential degradants using LC-DAD/ESI/APCI-Q-TOF-MS/MS. Microchemical Journal. 2021, 167, 106281. Impact Factor: 5.304.
• Identification and structural characterization of potential degraded impurities of ribociclib by time of flight -tandem mass spectrometry,and their toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis. 2021, 197, 113933. Impact Factor: 3.571.
• LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method. Journal of Analytical Science and Technology, 2020. 11 (54), 1-13. Impact Factor: 3.568.
• Target Specific Intracellular Quantification of Etoposide by Quadrupole-Time of Flight based Mass Spectroscopic Method. Journal of Chromatography B, 2020, 1152, 122233. Impact Factor: 3.318.
• Challenges and strategies for quantification of drugs in the brain: current scenario and future advancement. Critical Reviews in Analytical Chemistry, 2022, 52 (1), 93-105. Impact Factor: 5.686.
• Time of flight mass spectrometry based in vitro and in vivo metabolite profiling of ribociclib and their toxicity prediction. Journal of Chromatography B, 2020, 1147, 122142. Impact Factor: 3.318.
• Mass spectrometry based rapid quantitative bioanalysis of flibanserin; pharmacokinetic and brain tissue distribution study. Journal of Analytical Toxicology, 2020, 44 (6), 559–569. Impact Factor: 3.220.
• Amalgamation of Stress Degradation and Metabolite Profiling in Rat Urine and Feces for Characterization of Oxidative Metabolites of Flibanserin using UHPLCQ-TOF-MS/MS, H/D Exchange and NMR Technique. Journal of Chromatography B, 2020, 1139, 121993. Impact Factor: 3.318.
• Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products. International Journal of Pharmaceutics. 2020, 576, 119018. Impact Factor: 6.510.
• Advancement in analytical strategies for quantification of the multifaceted nitroxidative stress biomarker 3-Nitrotyrosine in biological matrices. Critical Reviews in Analytical Chemistry, 2020, 50 (3), 265-289. Impact Factor: 5.686.
• Establishment of a quantitative bioanalytical method for an acetylcholinesterase inhibitor Ethyl 3-(2-(4-fluorophenyl) amino)-4-phenylthiazol-5-yl)-3-oxopropanoate including its physicochemical characterization and in vitro metabolite profiling using Liquid Chromatography-Mass Spectrometry. Journal of Chromatography B, 2018. 1096; 214–222. Impact Factor: 3.318.
• Drug development and bioanalytical method validation for a novel anticancer molecule, 4-(Dimethylamino)-2-(p-tolylamino) thiazole-5-carbonitrile. Drug Development Research, 2018. 79, 391-399. Impact Factor: 5.004.
• Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International Journal of Pharmaceutics, 2018. 543 (1–2); 328-344. Impact Factor: 6.510.